文献速递肝病

索磷布韦/维帕他韦治疗透析合并HCV感染

Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.
PubMed 文献 · J Hepatol · 2019-06-11

这项II期单臂研究纳入59例基因1-6型HCV感染且接受透析的终末期肾病患者,给予索磷布韦/维帕他韦(400 mg/100 mg)每日一次口服12周。主要疗效终点SVR12为95%(95% CI 86-99%),56/59例达标;安全性方面最常见不良事件为头痛(17%)、乏力(14%)、恶心(14%)和呕吐(14%),11例(19%)报告严重不良事件且均判定与药物无关。

要点

  • 索磷布韦/维帕他韦(400 mg/100 mg)每日一次12周治疗透析合并HCV感染,SVR12为95%(95% CI 86-99%)。
  • 最常见不良事件为头痛(17%)、乏力(14%)、恶心(14%)和呕吐(14%)。
  • 11例(19%)报告严重不良事件,均判定与索磷布韦/维帕他韦无关。

核心结论

  • 索磷布韦/维帕他韦治疗12周在透析的终末期肾病患者中安全有效,SVR12为95%(95% CI 86-99%)。

研究设计与样本

  • II期单臂研究,纳入59例基因1-6型HCV感染且接受血液透析或腹膜透析的终末期肾病患者,开放标签给予索磷布韦/维帕他韦(400 mg/100 mg)每日一次口服12周。
  • 患者为HCV初治或经治、无肝硬化或代偿期肝硬化;既往接受过任何HCV NS5A抑制剂治疗者不符合入选条件。

主要发现

  • 56/59例达到SVR12(95%;95% CI 86-99%)。
  • 3例未达到SVR12:2例在治疗后第4周判定病毒学复发(其中1例提前终止研究治疗),1例在治疗后第4周达到SVR后死于自杀。
  • 最常见不良事件为头痛(17%)、乏力(14%)、恶心(14%)和呕吐(14%)。
  • 11例(19%)报告严重不良事件,均判定与索磷布韦/维帕他韦无关。

关键数值与推荐

  • 主要疗效终点为停药后12周持续病毒学应答(SVR12)比例,结果为95%(95% CI 86-99%)。
  • 主要安全性终点为因不良事件停用研究药物的患者比例。

临床怎么用

  • 对于接受透析的HCV感染终末期肾病患者,索磷布韦/维帕他韦(400 mg/100 mg)每日一次12周方案可考虑用于治疗。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Although off-label use of sofosbuvir-containing regimens occurs regularly in patients with hepatitis C virus (HCV) infection undergoing dialysis for severe renal impairment or end-stage renal disease (ESRD), these regimens are not licensed for this indication, and there is an absence of dosing recommendations in this population. This study evaluated the safety and efficacy of sofosbuvir/velpatasvir in patients with HCV infection with ESRD undergoing dialysis. METHODS: In this phase II, single-arm study, 59 patients with genotype 1-6 HCV infection with ESRD undergoing hemodialysis or peritoneal dialysis received open-label sofosbuvir/velpatasvir (400 mg/100 mg) once daily for 12 weeks. Patients were HCV treatment naive or treatment experienced without cirrhosis or with compensated cirrhosis. Patients previously treated with any HCV NS5A inhibitor were not eligible. The primary efficacy endpoint was the proportion of patients achieving sustained virologic response (SVR) 12 weeks after discontinuation of treatment (SVR12). The primary safety endpoint was the proportion of patients who discontinued study drug due to adverse events. RESULTS: Overall, 56 of 59 patients achieved SVR12 (95%; 95% CI 86-99%). Of the 3 patients who did not achieve SVR12, 2 patients had virologic relapse determined at post-treatment Week 4 (including 1 who prematurely discontinued study treatment), and 1 patient died from suicide after achieving SVR through post-treatment Week 4. The most common adverse events were headache (17%), fatigue (14%), nausea (14%), and vomiting (14%). Serious adverse events were reported for 11 patients (19%), and all were deemed to be unrelated to sofosbuvir/velpatasvir. CONCLUSIONS: Treatment with sofosbuvir/velpatasvir for 12 weeks was safe and effective in patients with ESRD undergoing dialysis. LAY SUMMARY: Sofosbuvir/velpatasvir is a combination direct-acting antiviral that is approved for treatment of patients with hepatitis C virus (HCV) infection. Despite the lack of dosing recommendations, sofosbuvir-containing regimens (including sofosbuvir/velpatasvir) are frequently used for HCV-infected patients undergoing dialysis. This study evaluated the safety and efficacy of sofosbuvir/velpatasvir for 12 weeks in patients with HCV infection who were undergoing dialysis. Treatment with sofosbuvir/velpatasvir was safe and well tolerated, resulting in a cure rate of 95% in patients with HCV infection and end-stage renal disease. Clinical Trial Number: NCT03036852.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Borgia SM, Dearden J, Yoshida EM, et al. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol. 2019. PMID: 31195062. doi:10.1016/j.jhep.2019.05.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。